University of Hertfordshire

PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery

Research output: Contribution to conferenceAbstractpeer-review

Standard

PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery. / MacKenzie, Louise; Wright, W.; Gatheral, T.; Warner, T.D.; Mitchell, J.A.

2012. Abstract from 4th European Workshop on Lipid Mediators, Paris, France.

Research output: Contribution to conferenceAbstractpeer-review

Harvard

MacKenzie, L, Wright, W, Gatheral, T, Warner, TD & Mitchell, JA 2012, 'PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery', 4th European Workshop on Lipid Mediators, Paris, France, 27/09/12 - 28/09/12. <http://workshop-lipid.eu/4EWLM/index.php>

APA

MacKenzie, L., Wright, W., Gatheral, T., Warner, T. D., & Mitchell, J. A. (2012). PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery. Abstract from 4th European Workshop on Lipid Mediators, Paris, France. http://workshop-lipid.eu/4EWLM/index.php

Vancouver

MacKenzie L, Wright W, Gatheral T, Warner TD, Mitchell JA. PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery. 2012. Abstract from 4th European Workshop on Lipid Mediators, Paris, France.

Author

MacKenzie, Louise ; Wright, W. ; Gatheral, T. ; Warner, T.D. ; Mitchell, J.A. / PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery. Abstract from 4th European Workshop on Lipid Mediators, Paris, France.

Bibtex

@conference{be43ae2b943d474c887a44fd68474f21,
title = "PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery",
abstract = "Pulmonary arterial hypertension is defined as a mean pulmonary artery pressure of greater than 25mmHg at rest. Current therapies modulate or mimic endogenous hormones released by endothelial cells that regulate vascular tone. These include prostacyclin (IP) receptor agonists (e.g. treprostinil sodium), phosphodiesterate type 5 inhibitors (e.g. sildenafil), and endothelin receptor antagonists (e.g. bosentan). However, none of these drugs cure the condition and new therapeutic approaches are currently under investigation. We and others have recently shown that the PPARbeta/delta agonist GW0742 induces vasodilatation of mouse and rat pulmonary arteries (Harrington et al 2010; Li et al 2012). However, the effect of PPARbeta/delta agonists on human pulmonary vessels has not been tested. Here we investigated the effects of two PPARbeta/delta agonists on human pulmonary artery tone in vitro using resting pressures in line with those seen in patients with pulmonary hypertension",
author = "Louise MacKenzie and W. Wright and T. Gatheral and T.D. Warner and J.A. Mitchell",
year = "2012",
month = sep,
language = "English",
note = "4th European Workshop on Lipid Mediators ; Conference date: 27-09-2012 Through 28-09-2012",

}

RIS

TY - CONF

T1 - PPARbeta/delta agonists GW0742 and GW501516 induce vasodilatation of human pulmonary artery

AU - MacKenzie, Louise

AU - Wright, W.

AU - Gatheral, T.

AU - Warner, T.D.

AU - Mitchell, J.A.

PY - 2012/9

Y1 - 2012/9

N2 - Pulmonary arterial hypertension is defined as a mean pulmonary artery pressure of greater than 25mmHg at rest. Current therapies modulate or mimic endogenous hormones released by endothelial cells that regulate vascular tone. These include prostacyclin (IP) receptor agonists (e.g. treprostinil sodium), phosphodiesterate type 5 inhibitors (e.g. sildenafil), and endothelin receptor antagonists (e.g. bosentan). However, none of these drugs cure the condition and new therapeutic approaches are currently under investigation. We and others have recently shown that the PPARbeta/delta agonist GW0742 induces vasodilatation of mouse and rat pulmonary arteries (Harrington et al 2010; Li et al 2012). However, the effect of PPARbeta/delta agonists on human pulmonary vessels has not been tested. Here we investigated the effects of two PPARbeta/delta agonists on human pulmonary artery tone in vitro using resting pressures in line with those seen in patients with pulmonary hypertension

AB - Pulmonary arterial hypertension is defined as a mean pulmonary artery pressure of greater than 25mmHg at rest. Current therapies modulate or mimic endogenous hormones released by endothelial cells that regulate vascular tone. These include prostacyclin (IP) receptor agonists (e.g. treprostinil sodium), phosphodiesterate type 5 inhibitors (e.g. sildenafil), and endothelin receptor antagonists (e.g. bosentan). However, none of these drugs cure the condition and new therapeutic approaches are currently under investigation. We and others have recently shown that the PPARbeta/delta agonist GW0742 induces vasodilatation of mouse and rat pulmonary arteries (Harrington et al 2010; Li et al 2012). However, the effect of PPARbeta/delta agonists on human pulmonary vessels has not been tested. Here we investigated the effects of two PPARbeta/delta agonists on human pulmonary artery tone in vitro using resting pressures in line with those seen in patients with pulmonary hypertension

M3 - Abstract

T2 - 4th European Workshop on Lipid Mediators

Y2 - 27 September 2012 through 28 September 2012

ER -